

## Product datasheet for TP725228

## CD252 (TNFSF4) Human Recombinant Protein

## **Product data:**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

| Product Type:                            | Recombinant Proteins   |
|--|--|
| Description:                             | Recombinant Human OX40L/TNFSF4 (N-His)   |
| Species:                                 | Human  |
| Expression cDNA Clone<br>or AA Sequence: | Gln51-Leu183   |
| Tag:                                     | N-8His   |
| Buffer:                                  | Lyophilized from a 0.2 um filtered solution of PBS, pH7.4  |
| Note:                                    | Recombinant Human OX40 Ligand is produced by our Mammalian expression system and the target gene encoding Gln51-Leu183 is expressed with a 8His tag at the N-terminus.   |
| Stability:                               | 12 months from date of despatch  |
| Locus ID:                                | 7292   |
| UniProt ID:                              | <u>P23510</u>  |
| Summary:                                 | OX40L, also known as CD252 is a type II transmembrane glycoprotein that is a member of the tumor necrosis factor (TNF) ligand family. OX40L is expressed on the surface of activated B cells, T cells, dendritic cells, and endothelial cells. It is an essential co-stimulatory molecule that plays an important role in the regulation of T-cell-mediated immunity. OX40L might play a role in T cell antigen-presenting cell (APC) interactions. In surface Ig- and CD4-stimulated B cells, this cytokine along with CD7 has been shown to provide CD28-independent costimulatory signals to T cells. The interaction of OX40 and OX40L on activated T cells in situ in tumors has been found to facilitate immune responses and subsequent tumor regression. |



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2023 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US